Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LGMN | Q99538 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178142 | 1.00 | MAPK1 (0.46) | MAPK1LGMNMAPTGAAKMT2A | |
| SCHEMBL21187305 | 0.88 | PRKDC (0.41) | ERBB2PRKDC | |
| Hydrochloric Acid SCHEMBL21177854 | 0.87 | PRKDC (0.41) | ERBB2PRKDC | |
| SCHEMBL30817827 | 0.87 | GAA (0.38) | MAPK1MAPTGAAKMT2ALMNA | |
| SCHEMBL30823325 | 0.87 | GAA (0.38) | MAPK1MAPTGAAKMT2ALMNA | |
| SCHEMBL21187360 | 0.87 | GAA (0.38) | MAPK1MAPTGAAKMT2ALMNA | |
| SCHEMBL21178261 | 0.86 | ERBB2 (0.40) | MAPTGSK3BERBB2PRKDC | |
| SCHEMBL21187311 | 0.86 | ERBB2 (0.40) | MAPTGSK3BERBB2PRKDC | |
| SCHEMBL21187288 | 0.84 | LMNA (0.41) | MAPTGAALMNASMN1; SMN2GSK3B | |
| SCHEMBL21177861 | 0.84 | LMNA (0.41) | MAPTGAALMNASMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1217/4885LGMN 3418/4885MAPT 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.